Patients with hepatocellular carcinoma (HCC) who develop immune-related adverse events (irAEs) following treatment with an immune checkpoint inhibitor (ICI) tend to have more favourable clinical outcomes, including better progression free survival (PFS) and objective response rate (ORR), reports a recent study.